Sponsor content

Collaborative Research and Licensing Opportunity: Compounds That Treat Malaria and Prevent Malaria Transmission

The invention relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmission.

Upvote 1 Comment

 Malaria is the single leading cause of death, especially among children, in the developing world. Malaria is caused by infection with parasites of the genus Plasmodium, transmitted by mosquitos. In addition to transmission, vital steps in the parasite lifecycle occur in the mosquito host. The invention offered for licensing relates to therapeutic compounds and related pharmaceutical compositions that can be used in the prevention and treatment of malaria infection. More specifically, the invention is drawn to compounds that may kill sexual and mosquito stage malaria parasites to block transmission. Specifically claimed is the antihistamine Ketotifen, which has demonstrated activity blocking parasite development in mosquitoes. Also claimed are treatments encompassing Ketotifen with other existing antimalarial drugs in a combination treatment aimed at multiple stages in the malaria life cycle.      

Potential Commercial Applications: 

  • Prevention and treatment of malaria infections

Competitive Advantages: 

  • Drugs that kill sexual and mosquito stages of the parasite are important for preventing and/or slowing the spread of malaria infection and ultimately for malaria eradication.
  • Primaquine, the only currently available drug shown to block transmission, is known to cause serious adverse side effects.

Development Stage: 

  • Pre-Clinical (animal data available)

Inventors:  Xin-zhuan Su and Dipak Raj (NIAID)

Publications: 

Eastman R. T. Pattaradilokrat S. Raj D. K. Dixit S. Deng B. Miura K. Yuan J. Tanaka T. Q. Johnson R. L. Jiang H.et al. 2013. A class of tricyclic compounds blocking malaria parasite oocyst development and transmission. Antimicrob. Agents Chemother.  57: 425–435.

Intellectual Property: 

US Patent # 9,375,424, US divisional patent application: 13/392,668, Worldwide patent applications: Canada 2772085, Europe 10812670.7, India 1684/DELNP/2012. Priority Application 61/237,417 filed August 27, 2009.  (HHS Reference No. E-283-2009)

Licensing and Collaborative Research Opportunity:The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in licensing or collaborative research to further co-develop this technology. For opportunities, please contact Peter Tung; 240-669-5483; peter.tung@nih.gov


Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).
25 Contributions
14 Followers
1 Following

No comments yet.